Clinical Trial: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Multiple Myeloma
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
Brief Summary:
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Read more